Company intelligence
Shinobi Therapeutics
Biotechnology Research
South San Francisco, US
39 employees
Founded 2023
3 public signals
About Shinobi Therapeutics
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
Verified activity
Signals from Shinobi Therapeutics
3 published signals
Research & Knowledge
Shinobi Therapeutics scientific advisor Georg Schett demonstrated the potential of CD19 CAR-T in autoimmune disease.
Reported by Dan Kemp
Products & Services
Shinobi Therapeutics designed its lead program NJA-201 from the ground up as an engineered, off-the-shelf, iPSC-derived cell therapy.
Reported by Dan Kemp
Legal & Regulatory
Shinobi Therapeutics is on track to file an IND later this year for its lead program NJA-201 and a Phase 1 study across multiple autoimmune indications.
Reported by Dan Kemp